



BioRx Wins 10th Annual Fast 55 Award

June 18, 2014



The *Cincinnati Business Courier* announced BioRx as the winner of its 2014 Fast 55 Award in the category of sales over \$100 million. The annual Fast 55 Award, Greater Cincinnati's premier awards program, recognizes the region's fastest-growing private companies.

Nearly 600 people from the region assembled on June 5 for an awards ceremony at the Hyatt Regency in Cincinnati. Winners in five size categories were recognized for the fastest growth over a three-year period. With 2013 sales of more than \$200 million, BioRx won in the largest category, with 78% growth.

BioRx (www.biorx.com) is a privately-owned specialty pharmacy based in Blue Ash, Ohio, and co-founded by Philip Rielly and Eric Hill. "We are honored to be recognized with such a significant award," said Rielly. "The Cincinnati region has a dynamic business environment, so we are very proud of our company and our people for what they've achieved."

The company began operations in 2004 with only three employees, specializing in the home treatment of hemophilia. Now in its 10th year, BioRx serves well over 1,000 patients nationwide who live with a variety of rare diseases, including bleeding disorders, immune deficiencies, autoimmune disorders, hereditary angioedema, alpha-1 antitrypsin deficiency, and various nutrition and digestive disorders. Its rapid growth has seen the company expand to nearly 250 employees in 2014, up 30% from a year ago.

"Strategic investments in new markets and therapy areas will continue to drive our growth," said Rielly. "That formula seems to work and we continue to enjoy the ride." ■

About Symmetric Capital

Symmetric Capital, a private equity firm focused on profitable growth companies in the United States and Canada, invested in BioRx in 2010. With the flexibility to invest in either minority or majority ownership positions, Symmetric structures transactions that meet both the immediate and the longer-term objectives of owners and managers – all without changing a company's entrepreneurial culture or introducing excessive debt that restricts growth. Since 1990, Symmetric's principals have built dozens of successful, collaborative partnerships, beginning in each case with an equity investment to fund growth, shareholder liquidity, debt repayment, a management-led buyout or a strategic acquisition.

Symmetric targets companies with at least \$10 million in revenues and \$2 million in operating profits. Sectors of interest include business and financial services, healthcare, technology, software, education, and consumer and industrial products. With over \$200 million in committed capital under management, Symmetric typically invests \$5-25 million in each company. Larger transactions can be funded in conjunction with our limited partners or with other co-investors. For more information on Symmetric, please visit www.symmetriccapital.com.